MedPage Today on MSN3d
Varipulse Returns; HCM Genes Reconsidered; Early Blood Test for Preeclampsia?To predict arrhythmic risk in carriers of filamin C truncating variants, a novel risk predictive model was developed based on ...
The instructions for use have been updated to address issues that led to a greater risk of neurovascular events in an early ...
Johnson & Johnson MedTech announced that it intends to resume the rollout of its Varipulse platform in the U.S. after a ...
GlobalData on MSN5d
Johnson & Johnson to resume market release of Varipulse catheter in USJohnson & Johnson is set to resume the limited market release of the Varipulse Catheter, a treatment option for atrial ...
J&J said it found no immediate procedure-related causes from the atrial fibrillation therapy but that risks can escalate if a ...
J.P. Morgan analysts said the findings of J&J’s investigation “could significantly hinder the product’s rollout in the U.S.
Bengaluru: Johnson & Johnson said on Friday it resumed the limited market release of its Varipulse heart device in the United States after an investigation found the devices operate as intended.
Johnson & Johnson (NYSE: JNJ) announced on Friday that it is set to recommence the limited market release of its VARIPULSE™ devices in the United States. The de ...
This summary covers recent health news, including Wyoming's first human H5N1 bird flu case, WHO's call for cancer warning ...
Medtronic (MDT) stock slips as the company reaffirms full-year outlook after delivering mixed financial for Q3 fiscal 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback